The Asian Development Bank (ADB) said on June 16 that it has approved a $25mn grant to help the Tajik government procure and deploy COVID-19 vaccines and strengthen Tajikistan's capacity to carry out its vaccination programme.
The project will finance the procurement and delivery of around 3mn doses of vaccine with safety boxes and syringes for over 1.3mn people from priority groups, or around 14% of the Tajik population. The government is aiming to vaccinate around 62.5% of the total population.
“COVID-19 vaccines save lives and are vital to accelerating the economic recovery in Tajikistan and elsewhere,” said ADB president Masatsugu Asakawa. “Through this project, and by working in close cooperation with Tajikistan’s development partners, ADB reaffirms its commitment to helping the country overcome the pandemic and restore normal life as soon as possible.”
The project will also finance international and national logistics to transport vaccines from their place of purchase to national, regional and district health facilities in the Central Asian country, Manila-headquartered ADB said.
The project will strengthen the capacity of the Ministry of Health and Social Protection of the Population to effectively manage the vaccination programme and conduct gender-sensitive and age-sensitive outreach campaigns and trainings, the development bank added.
Related Articles
Kuwait sovereign fund sues over London skyscraper that threatens light access
Kuwait's sovereign wealth fund has initiated legal action against one of the City of London's largest development projects, claiming the planned 36-storey tower will obstruct light to a building it ... more
Russian state VTB Bank to divest non-core assets
Russia’s second-largest bank state-controlled VTB plans to divest non-core assets unrelated to banking operations within the next five years, according to Interfax citing the bank's CEO, ... more
Azerbaijani banks report mixed financial performance in Q1 2025
Azerbaijan’s leading commercial banks released their financial results for the first quarter of 2025, showing a mixed performance in profitability, digitalisation, credit growth and capital ... more
Most Read
-
Serbian biotech Dren Bio sold to Sanofi for $1.9bn
1 month ago
-
Scandal surrounding Hungarian central bank’s investments spreads to Polish developer GTC
1 month ago
-
Israeli IDF troops engage in ground battle in Syria as airstrikes hit Palmyra
30 days ago
-
Who will be Serbia’s next prime minister?
1 month ago
-
TNT ammunition depot in Czechia explodes
30 days ago